Investors & Media

Feb 28, 2020 /

Feb 28, 2020 / Feb 28, 2020 /

Recent News

2/27/20

BELLUS Health Reports Full Year 2019 Financial Results and Business Highlights on BLU-5937
LAVAL, Quebec --(BUSINESS WIRE)-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial...
Read More
2/20/20

BELLUS Health to Present at Two Upcoming Healthcare Investor Conferences
LAVAL, Quebec --(BUSINESS WIRE)--Feb. 20, 2020-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced...
Read More
11/14/19

BELLUS Health Reports Financial and Operating Results for the Third Quarter Ended September 30, 2019
LAVAL, Quebec --(BUSINESS WIRE)--Nov. 14, 2019-- BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported...
Read More